PE20241892A1 - Inhibidores de la ras - Google Patents
Inhibidores de la rasInfo
- Publication number
- PE20241892A1 PE20241892A1 PE2024001555A PE2024001555A PE20241892A1 PE 20241892 A1 PE20241892 A1 PE 20241892A1 PE 2024001555 A PE2024001555 A PE 2024001555A PE 2024001555 A PE2024001555 A PE 2024001555A PE 20241892 A1 PE20241892 A1 PE 20241892A1
- Authority
- PE
- Peru
- Prior art keywords
- optionally substituted
- membered
- alkyl
- heteroalkyl
- relates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/504—Pyridazines; Hydrogenated pyridazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/547—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263298098P | 2022-01-10 | 2022-01-10 | |
| PCT/US2023/060288 WO2023133543A1 (en) | 2022-01-10 | 2023-01-09 | Ras inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20241892A1 true PE20241892A1 (es) | 2024-09-19 |
Family
ID=85199574
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2024001555A PE20241892A1 (es) | 2022-01-10 | 2023-01-09 | Inhibidores de la ras |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20250197423A1 (https=) |
| EP (1) | EP4463231A1 (https=) |
| JP (1) | JP2025503641A (https=) |
| KR (1) | KR20240132492A (https=) |
| CN (2) | CN118922423A (https=) |
| AR (1) | AR128234A1 (https=) |
| AU (1) | AU2023204824A1 (https=) |
| CA (1) | CA3246887A1 (https=) |
| CL (2) | CL2024002041A1 (https=) |
| CO (1) | CO2024010814A2 (https=) |
| CR (1) | CR20240276A (https=) |
| IL (1) | IL314033A (https=) |
| MX (1) | MX2024008561A (https=) |
| PE (1) | PE20241892A1 (https=) |
| TW (1) | TW202330553A (https=) |
| WO (1) | WO2023133543A1 (https=) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2023003060A (es) | 2020-09-15 | 2023-04-05 | Revolution Medicines Inc | Derivados indolicos como inhibidores de ras en el tratamiento del cancer. |
| WO2023240263A1 (en) * | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| CN119546613A (zh) * | 2022-07-08 | 2025-02-28 | 豪夫迈·罗氏有限公司 | 可用作kras抑制剂的大环化合物 |
| CN119522225A (zh) | 2022-09-29 | 2025-02-25 | 广州嘉越医药科技有限公司 | 大环衍生物及其应用 |
| WO2024104364A1 (zh) * | 2022-11-16 | 2024-05-23 | 杭州阿诺生物医药科技有限公司 | 一种pan-KRAS抑制剂化合物 |
| CR20250329A (es) | 2023-02-14 | 2025-09-12 | Hoffmann La Roche | Compuestos tricíclicos para el tratamiento del cáncer |
| EP4687905A1 (en) | 2023-03-30 | 2026-02-11 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| CN121263418A (zh) | 2023-04-07 | 2026-01-02 | 锐新医药公司 | 大环ras抑制剂 |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| IL326136A (en) | 2023-08-07 | 2026-03-01 | Revolution Medicines Inc | RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025104149A1 (en) * | 2023-11-16 | 2025-05-22 | F. Hoffmann-La Roche Ag | Macrocyclic compounds as kras mutant inhibitors for the treatment of cancer |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025213065A1 (en) * | 2024-04-05 | 2025-10-09 | Revolution Medicines, Inc. | Peptide conjugates |
| WO2025217307A1 (en) | 2024-04-09 | 2025-10-16 | Revolution Medicines, Inc. | Methods for predicting response to a ras(on) inhibitor and combination therapies |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2022005359A (es) | 2019-11-04 | 2022-06-02 | Revolution Medicines Inc | Inhibidores de ras. |
| CN120699039A (zh) * | 2019-11-04 | 2025-09-26 | 锐新医药公司 | Ras抑制剂 |
| WO2021091956A1 (en) * | 2019-11-04 | 2021-05-14 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202304452A (zh) * | 2021-04-09 | 2023-02-01 | 美商銳新醫藥公司 | Ｓｏｓ１抑制劑與ｒａｓ抑制劑於治療癌症之用途 |
| CA3217393A1 (en) * | 2021-05-05 | 2022-11-10 | Elena S. Koltun | Ras inhibitors |
| MX2023013912A (es) * | 2021-05-25 | 2024-02-12 | Revolution Medicines Inc | Metodos para inhibir ras. |
-
2023
- 2023-01-09 CN CN202380026429.5A patent/CN118922423A/zh active Pending
- 2023-01-09 CR CR20240276A patent/CR20240276A/es unknown
- 2023-01-09 MX MX2024008561A patent/MX2024008561A/es unknown
- 2023-01-09 AU AU2023204824A patent/AU2023204824A1/en active Pending
- 2023-01-09 CA CA3246887A patent/CA3246887A1/en active Pending
- 2023-01-09 KR KR1020247026507A patent/KR20240132492A/ko active Pending
- 2023-01-09 IL IL314033A patent/IL314033A/en unknown
- 2023-01-09 AR ARP230100052A patent/AR128234A1/es unknown
- 2023-01-09 EP EP23704026.6A patent/EP4463231A1/en active Pending
- 2023-01-09 TW TW112100804A patent/TW202330553A/zh unknown
- 2023-01-09 JP JP2024541159A patent/JP2025503641A/ja active Pending
- 2023-01-09 WO PCT/US2023/060288 patent/WO2023133543A1/en not_active Ceased
- 2023-01-09 PE PE2024001555A patent/PE20241892A1/es unknown
- 2023-01-09 CN CN202411889987.7A patent/CN119798279A/zh active Pending
-
2024
- 2024-07-04 CL CL2024002041A patent/CL2024002041A1/es unknown
- 2024-07-10 US US18/769,009 patent/US20250197423A1/en active Pending
- 2024-08-08 CO CONC2024/0010814A patent/CO2024010814A2/es unknown
-
2025
- 2025-03-28 CL CL2025000954A patent/CL2025000954A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL314033A (en) | 2024-09-01 |
| MX2024008561A (es) | 2024-07-22 |
| CO2024010814A2 (es) | 2024-08-20 |
| CL2024002041A1 (es) | 2024-12-20 |
| CN118922423A (zh) | 2024-11-08 |
| CR20240276A (es) | 2024-08-23 |
| JP2025503641A (ja) | 2025-02-04 |
| US20250197423A1 (en) | 2025-06-19 |
| EP4463231A1 (en) | 2024-11-20 |
| WO2023133543A1 (en) | 2023-07-13 |
| CA3246887A1 (en) | 2023-07-13 |
| AU2023204824A1 (en) | 2024-07-18 |
| CN119798279A (zh) | 2025-04-11 |
| TW202330553A (zh) | 2023-08-01 |
| AR128234A1 (es) | 2024-04-10 |
| CL2025000954A1 (es) | 2025-08-01 |
| KR20240132492A (ko) | 2024-09-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20241892A1 (es) | Inhibidores de la ras | |
| PE20240088A1 (es) | Inhibidores de ras | |
| PE20240089A1 (es) | Inhibidores de ras para el tratamiento del cancer | |
| PE20241476A1 (es) | Inhibidores de la ras | |
| CO2025015474A2 (es) | Inhibidores macrocíclicos de ras | |
| ECSP22012347A (es) | Derivados de 2-morfolinopiridina sustituidos como inhibidores de la cinasa atr | |
| PE20241063A1 (es) | Composiciones y metodos para la inhibicion de ras | |
| CR20250550A (es) | Inhibidores ras. | |
| PE20230825A1 (es) | Inhibidores de kras triciclicos fusionados | |
| PE20220931A1 (es) | Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina | |
| UY30603A1 (es) | Derivados de 2-aril-6-fenil-imidazo[1, 2-a]piridinas, su preparacion y su aplicacion en terapéutica | |
| CY1109227T1 (el) | Παραγωγα της 5-φαινυλο-4-μεθυλο-θειαζολ-2-υλ-αμινης ως αναστολεις των ενζυμων κινασης της φωσφατιδυλινοσιτολης 3 (p13) για την θεραπεια των φλεγμονωδων ασθενειων των αεραγωγων | |
| AR041347A1 (es) | Derivados de imidazol[1,2-a]pirazinas como inhibidores de quinasas dependientes de ciclinas | |
| AR063581A1 (es) | Imidazopirazinas como inhibidores de proteina quinasa | |
| DE602004002087D1 (de) | Bis(thio-hydrazid amid) verbindungen zur behandlung von mehrfach resistenten krebs | |
| BR112022003152A2 (pt) | Compostos farmacêuticos | |
| AR070263A1 (es) | Derivados de oxazepinopirimidinona arilamido sustituidos, utiles en el tratamiento y/o prevencion de enfermedades neurodegenerativas y otras, medicamentos que los contienen y proceso de preparacion e intermediarios. | |
| AR116771A1 (es) | Los neuroesteroides activos y sus métodos de uso | |
| AR048567A1 (es) | Derivados de benzoxazinona, su preparacion y composiciones farmaceuticas. | |
| PE20211769A1 (es) | Compuestos heteroaromaticos como inhibidores de vanina | |
| BR112021018692A2 (pt) | 1,1-dióxido de isotiazolidina e 1,4-butanossultona contendo derivados de rapamicina e usos dos mesmos | |
| AR080228A1 (es) | Derivados de piridina triciclicos medicamentos que contienen tales compuestos su uso y proceso para su preparacion | |
| CL2023002722A1 (es) | Derivados de morfolinas sustituidas y usos de estos | |
| AR132764A1 (es) | Inhibidores de tyk2 y sus usos | |
| AR036092A1 (es) | Un derivado de benzoxazepina, su uso y una composicion farmaceutica que lo comprende |